Clinical Trials

462 enrolled 30 charts

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02411656 2026-01-23

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

71 enrolled 11 charts

Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04095689 2026-01-23

INTEGRAL

Phase 2 Terminated

8 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT03310957 2025-12-12

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

185 enrolled 23 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03797326 2025-11-17

LEAP-005

BreastCNSGastrointestinalGynecologic

611 enrolled 27 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02957968 2025-08-28

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03106415 2025-06-27

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

23 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03366844 2025-04-29

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

66 enrolled 16 charts

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02734290 2025-03-10

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

29 enrolled 12 charts

882 enrolled 41 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

Phase 3 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

26 enrolled 14 charts

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03004183 2024-10-15

STOMP

57 enrolled 12 charts

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT02981303 2024-07-09

Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

64 enrolled 17 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Triple Negative Breast Neoplasms

NCT03621982 2024-06-13

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Phase 1 Terminated

78 enrolled 39 charts

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03639948 2024-04-11

NeoPACT

Phase 2 Active not recruiting

120 enrolled 12 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04148937 2024-04-05

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Phase 1 Completed

52 enrolled 21 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03121352 2023-10-06

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

30 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT02657889 2022-12-01

TOPACIO

122 enrolled 29 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02513472 2022-05-05

ENHANCE-1

258 enrolled 18 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

444 enrolled 19 charts

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

Phase 3 Completed

622 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03184558 2021-11-09

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Phase 2 Terminated

29 enrolled 10 charts